Zobrazeno 1 - 10
of 21
pro vyhledávání: '"59"'
Autor:
Xingpeng Han, Yin Li, Jian Hu, Yang Liu, Xiangning Fu, Xin Peng, Xiaofei Li, Tianyu He, Lunxu Liu, Heng Zhao, Yihe Wu, Jinming Xu, Deruo Liu, Lin Xu, Jinlin Cao
Publikováno v:
Clinical Lung Cancer. 23:170-176
Background Video-assisted thoracic surgery (VATS) has been widely used in the surgical treatment of thoracic diseases, and it suggested surgical and oncological advantages compared with open surgery. However, reports on the application of VATS in sur
Autor:
Gilberto de Castro Junior, Pedro Henrique Xavier Nabuco-de-Araujo, Carlos Alberto Buchpiguel, Marina Henkin Behar, Guilherme Harada, Mariane Tami Amano, Fernanda Frozoni Antonacio
Publikováno v:
Clinical Lung Cancer. 22:e708-e711
Clinical Practice Points Immunotherapy based on immune checkpoint inhibitors (ICIs) either alone or in combination with platinum-based chemotherapy has dramatically changed the therapeutic scenario in non–small cell lung cancer. However, only a sub
Autor:
James G. Schwade, William T. Brown, Fahed Fayad, Elizabeth Bossart, Beatriz E. Amendola, Jack F. Fowler, Silvio García, Zichong Huang, Hoke Han, Xiaodong Wu, Alberto de la Zerda
Publikováno v:
Clinical lung cancer. 8(8)
PURPOSE The aims of this study were to determine if image-guided robotic stereotactic radiosurgery by CyberKnife® Radiosurgery System using ablative radiation doses achieves acceptable local control in medically inoperable patients with early non–
Autor:
Myung-Ju Ahn, Tae Jung Kim, Tae Sung Kim, Keunchil Park, Bo Da Nam, Kyung Soo Lee, Yoon-La Choi, Myung Jin Chung
Publikováno v:
Clinical Lung Cancer. 20:e309-e316
Purpose To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic
Autor:
Hyun Ae Jung, Keunchil Park, Boram Lee, Myung-Ju Ahn, Seonggyu Byeon, Yoon-La Choi, Woong-Yang Park, Se-Hoon Lee, Jin Seok Ahn, Jong-Mu Sun
Publikováno v:
Clinical lung cancer. 21(3)
Background Genetic sequencing testing has become widely used to inform treatment decisions for advanced non-small cell lung cancer (NSCLC) patients. We analyzed benefits of genetic sequencing testing in real practice. Methods We retrospectively revie
Publikováno v:
Clinical Lung Cancer. 17:e77-e94
Background Secondary anaplastic lymphoma kinase (ALK) mutation may occur in patients with advanced ALK-positive non–small cell lung cancer treated with ALK inhibitors, but its nature is not well-known. Patients and Methods We analyzed tumor specime
Autor:
Eeva Rouvinen, Marjukka Myllärniemi, Katri Koli, Helena Lauri, Jari Räsänen, Eva Sutinen, Ilkka Ilonen, Karl B. Lemström, Juuso Paajanen, Olli Ritvos, Tommi Järvinen, Hely Ollila
Publikováno v:
Clinical lung cancer. 21(3)
Activin A has previously been associated with cancer cachexia and in vitro resistance to platinum-based chemotherapy. We studied circulating activin A concentrations as well as activin B and their antagonists' follistatin/follistatin-like 3 in presur
Autor:
Jens-Carsten Rückert, Christian Furth, Frank Hofheinz, Julian M. M. Rogasch, Christoph Chibolela, Dirk Böhmer, Maximilian von Laffert, Holger Amthauer, Sebastian Ochsenreither, Jens Neudecker, Nikolaj Frost
Publikováno v:
Clinical Lung Cancer. 21:264-272.e6
Background In patients with non–small-cell lung cancer (NSCLC), asphericity (ASP) of the primary tumor’s metabolic tumor volume (MTV) has shown prognostic significance. This study aimed at validation in an independent and sufficiently large cohor
Autor:
Anna Buder, Tomi Kovacevic, Branislav Perin, Anita Brandstetter, Jorun O. Buresch, Luka Brcic, Vladimir Stojsic, Robert Pirker, Bojan Zaric, Stefan Traint, Martin Filipits
Publikováno v:
Clinical lung cancer. 19(6)
Background We assessed the prognostic value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in patients with completely resected lung adenocarcinoma. Patients and Methods PD-1 and PD-L1 expression was determined using imm
Publikováno v:
Clinical Lung Cancer. 15:231-236
Background Thymic epithelial neoplasms are rare, with little prospective research to guide management. Surgery is the primary treatment modality for localized disease, but chemotherapy may be indicated in advanced disease. We performed a retrospectiv